Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer
暂无分享,去创建一个
A. Bardelli | E. Van Cutsem | J. Tabernero | M. Boedigheimer | D. Smith | A. Sartore-Bianchi | S. Siena | R. García-Carbonero | X. Guan | M. Karthaus | B. Bach | A. Ang | A. S. Jung | B. Twomey | D. Smith
[1] J. Zehnder,et al. IDH2 Mutation in a Patient with Metastatic Colon Cancer. , 2017, The New England journal of medicine.
[2] P. Gibbs,et al. Evaluation of emergent circulating tumor (ct) DNA RAS mutations in patients with metastatic colorectal cancer (mCRC) treated with panitumumab (pmab) monotherapy from the ASPECCT study , 2016 .
[3] A. Bardelli,et al. 2184 A phase 2 study of mechanisms of acquired resistance to panitumumab (pmab) plus irinotecan (iri) for metastatic colorectal cancer (mCRC) , 2015 .
[4] M. Peeters,et al. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials. , 2015, European journal of cancer.
[5] Beatriz Bellosillo,et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients , 2015, Nature Medicine.
[6] N. Lindeman,et al. Novel molecular insights from routine genotyping of colorectal carcinomas. , 2015, Human pathology.
[7] M. Salido,et al. Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer , 2015, Clinical Cancer Research.
[8] P. Angenendt,et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] A. Bardelli,et al. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. , 2014, Cancer discovery.
[10] L. Diaz,et al. Liquid biopsies: genotyping circulating tumor DNA. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] A. Bardelli,et al. Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer , 2014, Science Translational Medicine.
[12] J. Tabernero,et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.
[13] N. Rosenfeld,et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA , 2013, Nature.
[14] Qinghua Zhou,et al. Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Enzo Medico,et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.
[16] Johannes G. Reiter,et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.
[17] L. Mazzucchelli,et al. Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer , 2009, PloS one.
[18] S. Goodman,et al. Sensitive digital quantification of DNA methylation in clinical samples , 2009, Nature Biotechnology.